TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07105215: A Multicenter Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RC278 for Injection in the Treatment of Locally Advanced Unresectable or Metastatic Malignant Solid Tumor

Sponsor: RemeGen Co., Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 312 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$9,032,100

Rescue Site Savings

+$5,969,040

Unlock Full NCT07105215 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07105215 Rescue Dossier →